TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech reported preliminary 4Q 2025 VYJUVEK net revenue of $106-107 million and full-year 2025 revenue of $388-389 million. The company outlined an ambitious strategic vision to become a global leader in rare disease with plans to launch at least four marketed medicines by 2030, treating over 10,000 patients. The company maintains a strong balance sheet with $955 million in cash and investments, and expects combined non-GAAP R&D and SG&A expenses of $175-195 million in 2026.

Insights
JPMpC   neutral

Mentioned as launching tokenization initiatives without specific details about success or scale


KRYS   positive

The company demonstrated strong commercial execution with VYJUVEK generating $388-389 million in full-year 2025 revenue, successful European and Japanese launches, a robust clinical pipeline with multiple potential blockbuster launches expected within four years, a solid balance sheet of $955 million, and ambitious growth targets including four marketed medicines by 2030. The expansion of the KB801 registrational study and multiple clinical milestones planned for 2026 further support positive momentum.